Homocysteine is a risk factor for reduced ejection fraction in children with myocarditis: a single-center study

Chengjun Zhang1, Xiuwen Ren2, Yufan Xu2

  • 1Department of Pediatric, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.

PubMed

Insights

Elevated homocysteine (HCY) is linked to reduced ejection fraction (EF) in children with myocarditis. This risk is higher in males and overweight pediatric patients, indicating HCY as a potential biomarker.

Area of Science:

  • Cardiology
  • Pediatric Medicine
  • Biochemistry

Background:

  • The association between homocysteine (HCY) and ejection fraction (EF) is established in adults with cardiovascular diseases.
  • However, the relationship between HCY and EF in pediatric patients diagnosed with myocarditis is not well understood.

Purpose of the Study:

  • To investigate the potential relationship between homocysteine levels and ejection fraction in pediatric patients suffering from myocarditis.
  • To identify HCY as a possible risk factor for reduced EF in this specific pediatric population.

Main Methods:

  • A cross-sectional study involving 164 pediatric myocarditis patients (aged 1-18 years) was conducted.
  • Homocysteine levels and ejection fraction, measured by 3.0T cardiac magnetic resonance (CMR), were assessed.
  • Statistical analyses included t-tests, binary logistic regression, and restricted cubic spline (RCS) modeling, with subgroup analyses by age, sex, and BMI.

Main Results:

  • 31% of the pediatric patients exhibited reduced ejection fraction (EF < 55%).
  • Elevated homocysteine levels showed a significant positive association with the risk of reduced EF (OR = 1.033, P = 0.034).
  • Subgroup analyses revealed a stronger correlation between high HCY and reduced EF in males and in patients with a BMI ≥ 24 kg/m².

Conclusions:

  • Elevated homocysteine levels represent a significant risk factor for reduced ejection fraction in pediatric patients with myocarditis.
  • The association is particularly pronounced in male pediatric patients and those who are overweight.
  • These findings highlight the potential role of HCY as a biomarker for assessing cardiac function in pediatric myocarditis.
Abstract

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
769
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
647
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
496
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
344
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
1.3K
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
810